As Daré Biosciences approaches a pivotal year with a key product launch ahead, the company kicked off an open public offering, providing a chance for individuals to get involved for as little as $250.

“We’ve been trying for a long time to close that gap between 1% of private healthcare investment that goes into companies like ours that are developing products for conditions solely affecting women,” Johnson, the company’s CEO, told BioSpace in a recent interview.

And so, as Daré approaches a critical year with several product launches to come, the company in January kicked off a regulation A offering, providing a chance for individuals to get involved for as little as $250. Daré is officially seeking to raise $24.3 million with the offering.The idea has been picking up traction, according to Johnson.